Trial Outcomes & Findings for Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females (NCT NCT00787618)

NCT ID: NCT00787618

Last Updated: 2014-08-25

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

6 participants

Primary outcome timeframe

48 hours

Results posted on

2014-08-25

Participant Flow

Participant milestones

Participant milestones
Measure
50 mg Proellex Mild Impairment
50 mg Proellex single dose Female subjects with mild renal impairment function. 50 mg Proellex: Single dose
50 mg Proellex Moderate
50 mg Proellex, Female subjects with moderate renal impairment function. 50 mg Proellex: Single dose
50 mg Proellex, Normal
50 mg Proellex, Female subjects with normal renal function. 50 mg Proellex: Single dose
Overall Study
STARTED
3
0
3
Overall Study
COMPLETED
3
0
3
Overall Study
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 48 hours

Population: Study prematurely terminated

Outcome measures

Outcome data not reported

Adverse Events

50 mg Proellex Mild Impairment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

50 mg Proellex Moderate

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

50 mg Proellex, Normal

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Wike

Repros Therapeutics Inc.

Phone: 2817193402

Results disclosure agreements

  • Principal investigator is a sponsor employee Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights
  • Publication restrictions are in place

Restriction type: OTHER